Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,938 JPY | +1.73% | +1.70% | +15.67% |
15/04 | AstraZeneca: expects a sharp rise in kidney disease | CF |
11/04 | TVS Supply Chain's Supply of CKD Kits to TVS Motor Crosses 500,000 | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Industrial Machinery & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.67% | 1.25B | - | ||
-1.42% | 14.89B | B | ||
+25.00% | 4.92B | B | ||
-14.84% | 4.68B | C+ | ||
-11.99% | 4.52B | C+ | ||
+10.91% | 4.18B | B- | ||
-17.31% | 4.12B | C | ||
+13.00% | 3.73B | B- | ||
+29.08% | 3.43B | A- | ||
+0.73% | 3.31B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6407 Stock
- Ratings CKD Corporation